Home > Insider Trading > Filing (0001628280-23-036796)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	X4 Pharmaceuticals Inc	XFOR	Biological Products, (No Disgnostic Substances) (2836)	273181608

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1769914	Paula Ragan	C/O X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4Th Floor Boston MA 02134	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-11-01	199,531	$0.73	876,347	No	4	S	Direct
Common Stock	Disposition	2023-11-03	39,906	$0.90	836,441	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.
Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8043 to $0.9454, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.